Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Feb 15. doi: 10.1111/pcmr.12775. [Epub ahead of print]

PMID:
30767428
2.

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.

Chung C, Bryant A, Brown PD.

Cochrane Database Syst Rev. 2018 Jul 9;7:CD011492. doi: 10.1002/14651858.CD011492.pub2. Review.

PMID:
29987845
3.

Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.

Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, Yang TJ, Rosenblum MK, Ballangrud Å, Young RJ, Zhang Z, Beal K.

J Neurooncol. 2015 Oct;125(1):149-56. doi: 10.1007/s11060-015-1881-3. Epub 2015 Aug 26.

4.

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab.

Du Four S, Janssen Y, Michotte A, Van Binst AM, Van den Begin R, Duerinck J, Neyns B.

Cancer Med. 2018 Oct;7(10):4870-4879. doi: 10.1002/cam4.1726. Epub 2018 Aug 21.

5.

[Risk of radionecrosis after hypofractionated stereotactic radiotherapy targeting the postoperative resection cavity of brain metastases].

Keller A, Doré M, Antoni D, Menoux I, Thillays F, Clavier JB, Delpon G, Jarnet D, Bourrier C, Lefebvre F, Chibbaro S, Darié I, Proust F, Noël G.

Cancer Radiother. 2017 Aug;21(5):377-388. doi: 10.1016/j.canrad.2017.01.017. Epub 2017 May 24. French.

PMID:
28551018
6.

Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).

Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Grellard JM, Habrand JL, Emery E, Marie B, Thariat J, Stefan D.

Radiat Oncol. 2018 Jul 28;13(1):138. doi: 10.1186/s13014-018-1083-1.

7.

Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.

Kramer K, Pandit-Taskar N, Zanzonico P, Wolden SL, Humm JL, DeSelm C, Souweidane MM, Lewis JS, Cheung NK.

J Neurooncol. 2015 Jun;123(2):245-9. doi: 10.1007/s11060-015-1788-z. Epub 2015 May 6.

8.

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ.

Ann Oncol. 2016 Dec;27(12):2288-2294. doi: 10.1093/annonc/mdw417. Epub 2016 Sep 15.

PMID:
27637745
9.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

10.

Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.

Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL.

JAMA Oncol. 2015 Aug;1(5):668-76. doi: 10.1001/jamaoncol.2015.1206. Review.

11.

Therapeutic strategy of late cerebral radionecrosis. A retrospective study of 21 cases.

Carangelo B, Cerillo A, Mariottini A, Peri G, Rubino G, Mourmouras V, Palma L.

J Neurosurg Sci. 2010 Mar;54(1):21-8.

PMID:
20436395
12.

Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.

Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, Kim AH, Dunn GP, Robinson CG, Chicoine MR, Huang J, Abraham CD.

Radiother Oncol. 2018 Aug;128(2):266-273. doi: 10.1016/j.radonc.2018.06.017. Epub 2018 Jun 27.

PMID:
29960685
13.

Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy.

Stokes WA, Binder DC, Jones BL, Oweida AJ, Liu AK, Rusthoven CG, Karam SD.

J Neuroimmunol. 2017 Dec 15;313:118-122. doi: 10.1016/j.jneuroim.2017.10.006. Epub 2017 Oct 13.

PMID:
29153603
14.

[Melanoma brain metastases : Treatment options].

Rauschenberg R, Tabatabai G, Troost EG, Garzarolli M, Beissert S, Meier F.

Hautarzt. 2016 Jul;67(7):536-43. doi: 10.1007/s00105-016-3797-z. Review. German.

PMID:
27206449
15.

Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases.

Nguyen SM, Castrellon A, Vaidis O, Johnson AE.

Cureus. 2017 Jul 25;9(7):e1511. doi: 10.7759/cureus.1511. Review.

16.

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.

Hao C, Tian J, Liu H, Li F, Niu H, Zhu B.

Medicine (Baltimore). 2017 Jun;96(26):e7325. doi: 10.1097/MD.0000000000007325. Review.

17.

Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.

Robin TP, Breeze RE, Smith DE, Rusthoven CG, Lewis KD, Gonzalez R, Brill A, Saiki R, Stuhr K, Gaspar LE, Karam SD, Raben D, Kavanagh BD, Nath SK, Liu AK.

J Neurooncol. 2018 Oct;140(1):55-62. doi: 10.1007/s11060-018-2930-5. Epub 2018 Jun 16.

PMID:
29909499
18.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
19.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS.

Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18.

20.

Incidence and clinical course of radionecrosis in children with brain tumors. A 20-year longitudinal observational study.

Strenger V, Lackner H, Mayer R, Sminia P, Sovinz P, Mokry M, Pilhatsch A, Benesch M, Schwinger W, Seidel M, Sperl D, Schmidt S, Urban C.

Strahlenther Onkol. 2013 Sep;189(9):759-64. doi: 10.1007/s00066-013-0408-0. Epub 2013 Aug 22.

PMID:
23963155

Supplemental Content

Support Center